Vesalio Appoints Greg Cook as Chief Commercial Officer
Greg Cook joins Vesalio as Chief Commercial Officer to lead commercial strategy and execution across its thrombectomy platform.
Vesalio Expands International Neurovascular Portfolio with CE Mark of NeVa VS and NeVa 3.0 mm and Receives Additional FDA 510(k) Clearance for its Aspiration Catheters
Company advances global neuro-intervention footprint with new CE-marked devices for vasospasm and stroke, and expanded U.S. indications for aspiration catheters.
Vesalio Receives FDA 510(k) Clearance of enVast, the First Stent-Based Coronary Thrombectomy Technology
The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio’s commercial platform.
Vesalio Receives Two FDA 510(k) Clearances, Advancing Its Comprehensive Thrombectomy Platform with Aspiration Technology
The FDA clearances expand Vesalio’s thrombectomy portfolio to support its growth strategy in the rapidly expanding multi-billion-dollar global thrombectomy market.
Vesalio Announces Launch of pVasc Study in the U.S. While Featuring the pVasc Thrombectomy System at VIVA, VEITH, and TCT
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
Vesalio launches pVasc Thrombectomy System in the U.S. for peripheral occlusions
Introducing pVasc™ mechanical thrombectomy system for the safe and effective non-surgical removal of occlusions from the peripheral vasculature
VESALIO Introduces NeVa NET 4.0 mm Following International Success of NeVa NET 5.5 mm
Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology.
Vesalio appoints CFO and announces company headquarters in Dallas, Texas
Introducing pVasc™ mechanical thrombectomy system for the safe and effective non-surgical removal of occlusions from the peripheral vasculature
NeVa CLEAR Study results presented at ESMINT: innovative thrombectomy device achieves notable first-pass success and patient outcomes
Primary results from the CLEAR Study were presented at the ESMINT annual meeting in Marseille, France (4-6 September 2023), where Vesalio also announced the fifth anniversary of the international commercialization of the NeVa™ device.
Vesalio Announces Initial Use of its Uniquely Designed and FDA-approved NeVa VS Device
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
